AstraZeneca : Results of Annual General Meeting held on 11 April 2024

Total

votes

% of

% of

Votes cast in

cast as a

Votes

Resolution

Votes for

votes

Votes against

votes

% of

total

withheld

cast

cast

issued

share

capital

the year ended 31

1,205,690,871

99.88

1,470,816

0.12

1,207,161,687

77.87%

9,700,968

December 2023

2

To confirm dividends

1,215,177,590

99.94

790,189

0.06

1,215,967,779

78.44%

894,978

3

To reappoint

PricewaterhouseCoopers

1,208,377,872

99.36

7,843,545

0.64

1,216,221,417

78.45%

642,048

LLP as Auditor

To authorise the Directors

4 to agree the remuneration

1,215,717,786

99.98

279,816

0.02

1,215,997,602

78.44%

722,222

of the Auditor

5a

To re-elect Michel Demaré

1,197,325,871

98.49

18,416,788

1.51

1,215,742,659

78.42%

1,120,559

as a Director

5b

To re-elect Pascal Soriot as

1,206,729,787

99.26

9,036,742

0.74

1,215,766,529

78.42%

1,098,706

a Director

5c

To re-elect Aradhana Sarin

1,212,225,383

99.71

3,509,122

0.29

1,215,734,505

78.42%

1,129,532

as a Director

5d

To re-elect Philip Broadley

1,197,937,103

98.54

17,773,671

1.46

1,215,710,774

78.42%

1,153,360

as a Director

5e

To re-elect Euan Ashley as

1,213,332,278

99.80

2,375,199

0.20

1,215,707,477

78.42%

1,156,567

a Director

5f

To re-elect Deborah

1,215,396,504

99.97

318,525

0.03

1,215,715,029

78.42%

1,149,106

DiSanzo as a Director

5g

To re-elect Diana Layfield

1,215,424,019

99.98

292,514

0.02

1,215,716,533

78.42%

1,147,602

as a Director

5h

To elect Anna Manz as a

1,215,297,866

99.97

417,067

0.03

1,215,714,933

78.42%

1,149,091

Director

5i

To re-elect Sheri McCoy as

1,158,846,767

95.32

56,874,293

4.68

1,215,721,060

78.42%

1,142,920

a Director

5j

To re-elect Tony Mok as a

1,215,346,936

99.97

346,157

0.03

1,215,693,093

78.42%

1,170,931

Director

5k

To re-elect Nazneen

1,191,449,316

98.59

16,988,178

1.41

1,208,437,494

77.95%

8,426,242

Rahman as a Director

5l

To re-elect Andreas

1,215,395,253

99.97

314,359

0.03

1,215,709,612

78.42%

1,154,412

Rummelt as a Director

5m

To re-elect Marcus

947,479,100

77.93

268,252,536

22.07

1,215,731,636

78.42%

1,132,416

Wallenberg as a Director

To approve the Annual

6

Report on Remuneration for

the year ended 31

1,158,470,360

95.32

56,835,406

4.68

1,215,305,766

78.40%

1,558,941

December 2023

7

To approve the Directors'

761,702,826

64.43

420,514,520

35.57

1,182,217,346

76.26%

34,645,873

Remuneration Policy

To approve amendments to

8

the AstraZeneca

Performance Share Plan

769,577,451

65.34

408,204,003

34.66

1,177,781,454

75.97%

39,083,170

2020

9

To authorise limited political

1,184,223,861

98.00

24,219,787

2.00

1,208,443,648

77.95%

8,278,265

donations

10

To authorise the Directors

1,129,625,915

92.94

85,836,406

7.06

1,215,462,321

78.41%

1,259,562

to allot shares

11

To authorise the Directors

to disapply pre-emption

1,044,559,011

85.95

170,708,848

14.05

1,215,267,859

78.39%

1,454,048

rights

To authorise the Directors

12

to further disapply pre-

emption rights for

acquisitions and specified

997,629,834

82.33

214,143,713

17.67

1,211,773,547

78.17%

4,948,031

capital investments

13

To authorise the Company

1,205,828,976

99.23

9,306,860

0.77

1,215,135,836

78.38%

1,585,923

to purchase its own shares

14

To reduce the notice period

1,131,157,449

93.07

84,269,754

6.93

1,215,427,203

78.40%

1,294,801

for general meetings